Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis

– MODIFY2 study will evaluate efficacy in pain management for patients with mild-to-moderate osteoarthritis of the knee –

– Concurrent MODIFY-MRI imaging study will assess short-term physical modifications of the disease process –

SAN FRANCISCO, Aug. 23, 2017 – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of the 12-week, multicenter, double-blinded trial of approximately 60 patients follows previously announced Phase 1/2a clinical results supporting the safety, tolerability and intended mechanism of action of SB-061. In addition, Symic Bio plans to conduct a concurrent magnetic resonance imaging study, MODIFY-MRI, to assess the short-term physical modifications of the disease process resulting from SB-061 treatment. The MODIFY-MRI study includes an assessment of the process of inflammation, intended to provide data that are critical in further defining the potential for SB-061 to act as a long-term disease-modifying agent.

"We are encouraged by the performance of SB-061 in the clinic thus far," said Nathan Bachtell, M.D., Chief Medical Officer of Symic Bio. "By addressing the degradation of cartilage that is fundamental to disease pathology, SB-061 is intended to both manage pain and modify the course of disease. We are looking forward to efficacy results and MRI imaging data and expect to provide a top-line analysis of MODIFY2 and MODIFY-MRI results in early 2018."

Additional information on the design of SB-061 for the treatment of osteoarthritis can be found at https://youtu.be/LNiHLtMiV8s or www.symic.bio/pipeline/osteoarthritis/.

SB-061 from Symic Bio

In the osteoarthritis disease state, the primary proteoglycan in the cartilage extracellular matrix, aggrecan, is degraded and lost. With the loss of aggrecan, cartilage is vulnerable to pro-inflammatory cytokines that cause degradation, leading to additional breakdown of the extracellular matrix in the joint. SB-061, a therapeutic bioconjugate inspired by aggrecan, is a drug delivered directly to the joint via an intra-articular injection. SB-061 directly targets the degrading extracellular matrix, thereby reducing the inflammatory cycle that drives the signs and symptoms of progressive osteoarthritis. The goal of this approach is to modify the course of disease by reducing joint degradation and concurrently decreasing pain and functional decline due to inflammation in the joint.

For more information on the MODIFY2 Phase 2 trial for osteoarthritis of the knee, please see https://clinicaltrials.gov/ct2/show/NCT03231280.

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contact
Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts
David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com